DOULEUR DES CHIENS ET CHATS
Antinerve growth factor monoclonal antibodies for the control of pain in dogs and cats
Are nutraceuticals better than carprofen at controlling osteoarthritis in dogs?
Protective effects of platelet-rich plasma against lidocaine cytotoxicity on canine articular chondrocytes
Adverse effects of morphine, methadone and tramadol in the postoperative period of dogs undergone vertebral surgery: 180 cases (2011-2016)
Review of the cardiovascular toxicity of amitriptyline treatment for canine neuropathic pain
L'observance thérapeutique dans l'arthrose chez le chien : données de la littérature et enquête auprès des vétérinaires et des propriétaires de chiens arthrosiques
1/ Antinerve growth factor monoclonal antibodies for the control of pain in dogs and cats
Enomoto, M., Mantyh, PW., Murrell, J., Innes, JF., Lascelles, BDX
Veterinary Record Published Online First: 27 October 2018
Nerve growth factor (NGF) is essential for the survival of sensory and sympathetic neurons during development.
However, in the adult, NGF and its interaction with tropomyosin receptor kinase A receptor (TrkA) has been found to play a critical role in nociception and nervous system plasticity in pain conditions. Thus, various monoclonal antibody (mAb) therapies targeting this pathway have been investigated in the development of new pharmacotherapies for chronic pain.
Although none of the mAbs against NGF are yet approved for use in humans, they look very promising for the effective control of pain in humans. Recently, species-specific anti-NGF mAbs for the management of osteoarthritis (OA)-associated pain in dogs and cats has been developed, and early clinical trials have been conducted. Anti-NGF therapy looks to be both very effective and very promising as a novel therapy against chronic pain in dogs and cats.
> This review outlines the mechanism of action of NGF and reviews its role of NGF in osteoarthritis, reviews research in rodent OA models and the current status of the development of anti-NGF mAbs in humans.
Furthermore, we describe and discuss the recent development of species-specific anti-NGF mAbs for the treatment of OA-associated pain in veterinary medicine.
2/ Are nutraceuticals better than carprofen at controlling osteoarthritis in dogs?
Belshaw, Z., Brennan, M.
Veterinary Record, 2018, 183, 507-508.
Clinical scenario: Sally, a 12-year-old female neutered black Labrador, is presented to you with right forelimb lameness.
She has decreased range of movement in both hips and the right elbow. You radiograph her hips, stifles, shoulders and elbows and find she has significant osteoarthritis in all joints.
You recommend a course of carprofen (Rimadyl; Zoetis), but Sally’s owner takes daily glucosamine for her own osteoarthritis and wants to know if it works in dogs.
You wonder if a nutraceutical could control the clinical signs of osteoarthritis better than carprofen?
In [dogs with osteoarthritis] is a [glucosamine and chondroitin supplement v carprofen] better at [reducing the clinical signs of osteoarthritis]?
3/ Protective effects of platelet-rich plasma against lidocaine cytotoxicity on canine articular chondrocytes
Erika Bianchini, Francesco Mancini, Antonio Di Meo, Anna Stabile, Sandra Buratta, Livia Moscati, Alessandra Pistilli, Claudia Floridi, Marco Pepe and Elisabetta Chiaradia
Acta Veterinaria Scandinavica2018, 60:63, Published: 26 October 2018
Lidocaine (LD) is one of the most commonly used local anesthetics for performing arthroscopic surgery and managing of osteoarthritic pain in both human and veterinary medicine. However, over the last years, several studies have focused on the chondrotoxic effects of LD.
In order to ensure that intra-articular lidocaine is safe to use, treatments aimed at mitigating chondrocyte death have recently been investigated. The aim of this study is to evaluate the possible protective effects of platelet-rich plasma (PRP) against LD cytotoxicity on canine articular chondrocytes.
Articular canine chondrocytes, were exposed to 1% or 1.8% LD alone or in co-presence with 10% PRP for 30 min. In order to evaluate the effects of PRP pre-treatments, experiments were carried out on cells cultured in serum-free medium-or in medium supplemented with 10% PRP or 10% fetal bovine serum. Cell viability was evaluated by methyl thiazolyl tetrazolium assay and cell apoptosis was analyzed by flow cytometry using annexin V-fluorescein isothiocyanate/propidium iodide.
The results showed that LD significantly reduced canine chondrocytes viability, probably due to apoptosis induction.
Pre-treatment or the co-presence of PRP in the media restored the number of viable chondrocytes.
The PRP also seemed to protect the cells from LD-induced apoptosis.
Pre-treatments and/or the simultaneous administration of PRP reduced LD-induced cytotoxicity in canine chondrocytes.
Further in vivo studies are required to determine whether PRP can be used as a save protective treatment for dogs receiving intra-articular LD injections.
4/ Adverse effects of morphine, methadone and tramadol in the postoperative period of dogs undergone vertebral surgery: 180 cases (2011-2016)
Ripplinger A et al.
Pesq. Vet. Bras., 2018, vol.38, n.7, pp.1431-1437.
Postoperative pain in dogs undergone vertebral surgery is classified as severe and it’s important an adequate approach to it, because it can influence recovery time, quality of life and surgery outcome.
Opioids are indicated for postoperative pain treatment in these surgeries.
Opioids may have adverse effects that may require attention.
There are few clinical studies that present the adverse effects of these analgesics in canine postoperative period.
The aim of this retrospective study was to present the adverse effects of morphine, methadone and tramadol in canine vertebral surgery postoperative period.
There were revised the postoperative records of 180 dogs and the changes resulted from the opioids use were noted.
The adverse effects observed were anorexia, hyporexia, vomiting, vocalization, bradycardia, hypothermia, panting, sedation.
Pain was also observed in some dogs.
A significant difference was found in anorexia between dogs treated with morphine and tramadol and methadone and tramadol.
Significant difference was also found in pain between dogs treated with morphine and tramadol.
The association of metamizole and morphine or metamizole and methadone was not different in relation to the adverse effects.
There was also no difference with the dosage variation and the adverse effects.
In conclusion, morphine, methadone and tramadol have adverse effects when used for pain control in the postoperative period of dogs submitted to vertebral surgery.
Anorexia, hypophagia and emesis were frequent the adverse effects observed with morphine and methadone and, despite tramadol presented less adverse effects, its use may be not beneficial in the studied doses when we consider the degree of pain, however more controlled studies with clinical situation are needed to confirm this.
PDF (en portugais) à http://www.scielo.br/pdf/pvb/v38n7/1678-5150-pvb-38-07-1431.pdf
5/ Review of the cardiovascular toxicity of amitriptyline treatment for canine neuropathic pain
Saikaew Sutayatram, Kumpanart Soontornvipart, Piyasiri Glangosol
Thai J. Vet. Med., 2018, vol 48 No 4, p. 515-528
6/ L'observance thérapeutique dans l'arthrose chez le chien : données de la littérature et enquête auprès des vétérinaires et des propriétaires de chiens arthrosiques